Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
World Neurosurg ; 143: e215-e223, 2020 11.
Article in English | MEDLINE | ID: mdl-32712400

ABSTRACT

BACKGROUND: Previous studies have suggested that interleukin (IL)-17A is a key factor that contributes to intervertebral disc degeneration (IDD), whereas autophagy has been shown to be a protective mechanism in IDD. However, the relationship between IL-17A and autophagy in IDD remains to be fully elucidated. This study sought to evaluate the association between IL-17 and autophagy and the potential mechanism through which IL-17A affects autophagy in IDD. METHODS: Intervertebral disc specimens were collected from 10 patients with lumbar disc herniation. Human degenerated nucleus pulposus (NP) cells were cultured in the presence or absence of IL-17A treatment. Western blot and monodansylcadaverine staining were used to measure autophagy levels in human degenerated NP cells. Subsequently, phosphatidylinositol 3-kinase (PI3K)/Akt/Bcl-2 pathway inhibitors were used to reveal the potential mechanism. RESULTS: IL-17A treatment inhibited the autophagic activity in human NP cells in a time- and dose-dependent manner. Moreover, monodansylcadaverine staining showed that cells treated with IL-17A had significantly fewer changes in their autophagic vacuoles compared with control-treated cells. After IL-17A treatment, expression levels of PI3K, p-Akt, and Bcl-2 in NP cells were significantly increased. Further assays with PI3K/Akt/Bcl-2 inhibitors revealed that IL-17A suppressed autophagy in NP cells by activating the PI3K/Akt/Bcl-2 signaling pathway. CONCLUSIONS: These data suggest that IL-17A promotes IDD by inhibiting autophagy through activation of the PI3K/Akt/Bcl-2 signaling pathway and may offer new insights for targeted therapy of this disease.


Subject(s)
Autophagy/immunology , Interleukin-17/immunology , Intervertebral Disc Degeneration/immunology , Nucleus Pulposus/immunology , Phosphatidylinositol 3-Kinases/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Aged , Autophagy/drug effects , Cells, Cultured , Female , Humans , Interleukin-17/pharmacology , Intervertebral Disc Degeneration/metabolism , Intervertebral Disc Displacement , Male , Middle Aged , Nucleus Pulposus/cytology , Nucleus Pulposus/metabolism , Phosphatidylinositol 3-Kinases/drug effects , Phosphatidylinositol 3-Kinases/pharmacology , Phosphoinositide-3 Kinase Inhibitors , Phosphorylation , Proto-Oncogene Proteins c-akt/antagonists & inhibitors , Proto-Oncogene Proteins c-akt/drug effects , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Proto-Oncogene Proteins c-bcl-2/drug effects , Signal Transduction
2.
Biomed Pharmacother ; 99: 725-734, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29710470

ABSTRACT

Intervertebral disc degeneration (IDD) is the most common cause leading to low back pain, a highly prevalent, costly and crippling condition worldwide. Overexpression of miR-21 has been shown to promote proliferation of nucleus pulposus (NP) cells. However, it remains unclear whether miR-21 can promote the degradation of type II collagen (Col II) and aggrecan, two main extracellular matrix components within the disc. Here, the miRNA microassay assay identified 29 differentially expressed miRNAs in NP tissues from IDD patients compared with healthy controls. Following qRT-PCR validation, miR-21 expression was significantly upregulated in degenerated NP tissues, and showed a positive correlation with disc degeneration grade. Through gain-of-function and loss-of-function studies in human NP cells, miR-21 was shown to inhibit autophagy and then upregulate the expression of matrix metalloproteinase (MMP)-3 and MMP-9, leading to increased degradation of Col II and aggrecan. Mechanistically, phosphatase and tensin homolog (PTEN) was identified as a direct target of miR-21, and activated PTEN/ Akt/mammalian target of rapamycin (mTOR) signaling pathway was involved in miR-21-induced autophagy inhibition and Col II and aggrecan breakdown. Taken together, these results suggest that miR-21 contributes to Col II and aggrecan catabolism by inhibiting autophagy via the PTEN/Akt/mTOR signaling pathway in human NP cells.


Subject(s)
Extracellular Matrix/genetics , Intervertebral Disc Degeneration/genetics , MicroRNAs/genetics , Nucleus Pulposus/pathology , Adolescent , Aged , Aggrecans/metabolism , Autophagy/genetics , Case-Control Studies , Collagen Type II/metabolism , Female , Humans , Intervertebral Disc Degeneration/pathology , Male , Middle Aged , Nucleus Pulposus/cytology , PTEN Phosphohydrolase/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/genetics , TOR Serine-Threonine Kinases/metabolism , Young Adult
3.
Medicine (Baltimore) ; 97(3): e9382, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29504970

ABSTRACT

Multilevel cervical reconstruction and fusion after cervical tuberculosis has always been a challenge. The current implantation materials for cervical fusion, including titanium mesh, cage, and plate are limited by its inferior biological mechanical characteristics and the properties of the metallic material. This has led to the increased risk of recurrent infection after surgery. In addition, the unique nature of tuberculosis infection results in the low rate of cervical fusion and high risk of recurrence. This case report presents 1 patient who suffered from long segmental cervical tuberculosis and had reconstruction surgery using a vascularized fibula graft. The patient had successful graft incorporation 3 months postsurgery and was followed-up for 30 months. In this review, we detail the advantages of using vascularized fibular grafts and compare it with other types of grafts.


Subject(s)
Cervical Vertebrae/surgery , Fibula/blood supply , Fibula/transplantation , Spinal Fusion , Tuberculosis, Spinal/surgery , Female , Humans , Middle Aged
4.
Cell Prolif ; 50(1)2017 Feb.
Article in English | MEDLINE | ID: mdl-27859817

ABSTRACT

The term long non-coding RNA (lncRNA) refers to a group of RNAs with length more than 200 nucleotides, limited protein-coding potential, and having widespread biological functions, including regulation of transcriptional patterns and protein activity, formation of endogenous small interfering RNAs (siRNAs) and natural microRNA (miRNA) sponges. Intervertebral disc degeneration (IDD) and osteoarthritis (OA) are the most common chronic, prevalent and age-related degenerative musculoskeletal disorders. Numbers of lncRNAs are differentially expressed in human degenerative nucleus pulposus tissue and OA cartilage. Moreover, some lncRNAs have been shown to be involved in multiple pathological processes during OA, including extracellular matrix (ECM) degradation, inflammatory responses, apoptosis and angiogenesis. In this review, we summarize current knowledge concerning lncRNAs, from their biogenesis, classification and biological functions to molecular mechanisms and therapeutic potential in IDD and OA.


Subject(s)
Intervertebral Disc Degeneration/genetics , Intervertebral Disc Degeneration/physiopathology , Osteoarthritis/genetics , Osteoarthritis/physiopathology , RNA, Long Noncoding/metabolism , Apoptosis/genetics , Extracellular Matrix/genetics , Extracellular Matrix/metabolism , Humans , Intervertebral Disc Degeneration/metabolism , Osteoarthritis/metabolism , RNA Interference , RNA, Long Noncoding/genetics , Synoviocytes/cytology , Synoviocytes/metabolism , Transcriptome
5.
Clin Chim Acta ; 457: 27-35, 2016 Jun 01.
Article in English | MEDLINE | ID: mdl-27018178

ABSTRACT

Autophagy is a homeostatic mechanism through which intracellular damaged organelles and proteins are degraded and recycled in response to increased metabolic demands or stresses. Although primarily cytoprotective, dysfunction of autophagy is often associated with many degenerative diseases, including intervertebral disc (IVD) degeneration (IDD). As a main contributing factor to low back pain, IDD is the pathological basis for various debilitating spinal diseases. Either higher or lower levels of autophagy are observed in degenerative IVD cells. Despite the precise role of autophagy in disc degeneration that is still controversial, with difference from protection to aggravation, targeting autophagy has shown promise for mitigating disc degeneration. In the current review, we summarize the changes of autophagy in degenerative IVD cells and mainly discuss the relationship between autophagy and IDD. With continued efforts, modulation of the autophagic process could be a potential and attractive therapeutic strategy for degenerative disc disease.


Subject(s)
Autophagy , Intervertebral Disc Degeneration/immunology , Humans
6.
Clin Chim Acta ; 450: 262-72, 2015 Oct 23.
Article in English | MEDLINE | ID: mdl-26341894

ABSTRACT

Intervertebral disk degeneration (IDD) is the most common diagnosis in patients with low back pain, a main cause of musculoskeletal disability in the world. Interleukin-1 (IL-1) ß is the most important member of the IL-1 family, and has a strong pro-inflammatory activity by stimulating the secretion of multiple pro-inflammatory mediators. IL-1ß is highly expressed in degenerative intervertebral disk (IVD) tissues and cells, and it has been shown to be involved in multiple pathological processes during disk degeneration, including inflammatory responses, matrix destruction, angiogenesis and innervation, cellular apoptosis, oxidative stress and cellular senescence. However, inhibition of IL-1ß is found to promote extracellular matrix (ECM) repair and protect against disk regeneration. In this review, after a brief description of IL-1ß signaling, we mainly focus on the expression profiles, roles and therapeutic potential of IL-1ß in IDD. A better understanding will help develop novel IL-1ß-based therapeutic interventions for degenerative disk disease.


Subject(s)
Interleukin-1beta , Intervertebral Disc Degeneration , Animals , Gene Expression Regulation , Humans , Interleukin-1beta/biosynthesis , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Intervertebral Disc Degeneration/drug therapy , Intervertebral Disc Degeneration/etiology , Intervertebral Disc Degeneration/metabolism , Intervertebral Disc Degeneration/pathology , Molecular Targeted Therapy , Signal Transduction
7.
Clin Chim Acta ; 448: 238-46, 2015 Aug 25.
Article in English | MEDLINE | ID: mdl-26162271

ABSTRACT

Intervertebral disc degeneration (IDD) is the most common diagnosis in patients with low back pain, a leading cause of musculoskeletal disability worldwide. The major components of extracellular matrix (ECM) within the discs are type II collagen (Col II) and aggrecan. Excessive destruction of ECM, especially loss of Col II and aggrecan, plays a critical role in promoting the occurrence and development of IDD. Matrix metalloproteinases (MMPs) and a disintegrin and metalloprotease with thrombospondin motifs (ADAMTSs) are primary enzymes that degrade collagens and aggrecan. There is a large and growing body of evidence that many members of MMPs and ADAMTSs are highly expressed in degenerative IVD tissue and cells, and are closely involved in ECM breakdown and the process of disc degeneration. In contrast, targeting these enzymes has shown promise for promoting ECM repair and mitigating disc regeneration. In the current review, after a brief description regarding the biology of MMPs and ADAMTSs, we mainly focus on their expression profiles, roles and therapeutic potential in IDD. A greater understanding of the catabolic pathways involved in IDD will help to develop potential prophylactic or regenerative biological treatment for degenerative disc disease in the future.


Subject(s)
ADAM Proteins/metabolism , Intervertebral Disc Degeneration/metabolism , Matrix Metalloproteinases/metabolism , ADAM Proteins/genetics , Animals , Gene Expression Profiling , Humans , Intervertebral Disc Degeneration/drug therapy , Matrix Metalloproteinases/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...